{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:52:01Z","timestamp":1777521121840,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10792-018-1040-x","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T02:11:46Z","timestamp":1543198306000},"page":"2161-2169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by periodic fluorescence angiography and optical coherence tomography"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4484-1947","authenticated-orcid":false,"given":"Asl\u0131","family":"Vural","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130rfan","family":"Perente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130smail Umut","family":"Onur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdem","family":"Eri\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Seymen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcls\u00fcm Oya","family":"Herg\u00fcnsel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zg\u00fcl","family":"Saliho\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadime Ulviye","family":"Yi\u011fit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,26]]},"reference":[{"key":"1040_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S1091-8531(99)70091-1","volume":"3","author":"PG Stenkuller","year":"1999","unstructured":"Stenkuller PG, Du L, Gilbert C, Foster A, Colins ML, Coats DK (1999) Childhood blindness. J AAPOS 3:26\u201332","journal-title":"J AAPOS"},{"key":"1040_CR2","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00417-008-0865-9","volume":"246","author":"P Kwinta","year":"2008","unstructured":"Kwinta P, Bik-Multanowski M, Mitkowska Z, Tomasik T, Pietrzyk JJ (2008) The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 246:1467\u20131475","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1040_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1167\/iovs.13-13429","volume":"55","author":"H Wang","year":"2014","unstructured":"Wang H, Yang Z, Jiang Y, Flannery J, Hammond S, Kafri T, Vemuri SK, Jones B, Hartnett ME (2014) Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 55:737\u2013744","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1040_CR4","first-page":"34557","volume":"14","author":"P Geisen","year":"2008","unstructured":"Geisen P, Peterson LJ, Mariniuk D (2008) Neutralizing anti-body to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. Mol Vis 14:34557","journal-title":"Mol Vis"},{"key":"1040_CR5","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/archophthalmol.2008.1","volume":"126","author":"L Kong","year":"2008","unstructured":"Kong L, Mintz-Hittner HA, Penland Kretzer FL, Chevez-Barrios P (2008) Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 126:1161\u20131163","journal-title":"Arch Ophthalmol"},{"key":"1040_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/IAE.0b013e3181644ad2","volume":"28","author":"GA Lalwani","year":"2008","unstructured":"Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, Hess D, Johnson RA, Puliafito CA (2008) Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 28:13\u201318","journal-title":"Retina"},{"key":"1040_CR7","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","volume":"28","author":"HA Mintz-Hittner","year":"2008","unstructured":"Mintz-Hittner HA, Kuffel RR Jr (2008) Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 28:831\u2013838","journal-title":"Retina"},{"key":"1040_CR8","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","volume":"92","author":"S Kusaka","year":"2008","unstructured":"Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, Fujikado T (2008) Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 92:1450\u20131455","journal-title":"Br J Ophthalmol"},{"key":"1040_CR9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","volume":"33","author":"MA Martinez-Castellanos","year":"2013","unstructured":"Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML, Kon-Jara VA, Garcia-Aguirre G, Guerrero-Naranjo JL, Chan RV, Quiroz-Meracado H (2013) Longterm effect of antiangiogenic therapy for retinopathy of prematurity up to 5\u00a0years of follow-up. Retina 33:329\u2013338","journal-title":"Retina"},{"key":"1040_CR10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","volume":"97","author":"MA Castellanos","year":"2013","unstructured":"Castellanos MA, Schwartz S, Garc\u00eda-Aguirre G, Quiroz-Mercado H (2013) Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol 97:816\u2013819","journal-title":"Br J Ophthalmol"},{"key":"1040_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, the BEAT-ROP Cooperative Group (2011) Efficacy of intravitreal bevacizumab for stage 3 retinopathy of prematurity: preliminary results of the BEAT-ROP clinical trial. N Engl J Med 364:603\u2013615","journal-title":"N Engl J Med"},{"key":"1040_CR12","first-page":"207\u2013214, 225\u201323","volume":"79","author":"LP Orozco-G\u00f3mez","year":"2011","unstructured":"Orozco-G\u00f3mez LP, Hern\u00e1ndez-Salazar L, Moguel-Ancheita S, Ram\u00edrez-Moreno MA, Morales-Cruz MV (2011) Laser-ranibizumab treatment for retinopathy of prematurity in umbral-preumbral disease. Three years of experience. Cardiology 79:207\u2013214, 225\u2013232","journal-title":"Cardiology"},{"key":"1040_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.5301\/ejo.5000166","volume":"22","author":"R Autrata","year":"2012","unstructured":"Autrata R, Krejc\u00edrov\u00e1 I, Senkov\u00e1 K, Holosova M, Dolezel Z, Borek I (2012) Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol 22:687\u2013694","journal-title":"Eur J Ophthalmol"},{"key":"1040_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2011","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N et al (2011) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171\u2013185","journal-title":"Angiogenesis"},{"issue":"1","key":"1040_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000364809","volume":"53","author":"AG Salman","year":"2015","unstructured":"Salman AG, Said AM (2015) Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity. Opthalmic Res 53(1):15\u201320","journal-title":"Opthalmic Res"},{"issue":"6","key":"1040_CR16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5301\/ejo.5000938","volume":"27","author":"EA Sukgen","year":"2017","unstructured":"Sukgen EA, S\u00f6ker G, Ko\u00e7luk Y, G\u00fclek B (2017) Effect of intravitreal aflibercept on central retinal arterial blood flow in type 1 retinopathy of prematurity. Eur J Ophthalmol 27(6):751\u2013755","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"1040_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1542\/peds.2012-2996","volume":"131","author":"WM Fierson","year":"2013","unstructured":"Fierson WM (2013) Screening examination of premature infants for\u00a0retinopathy of prematurity. American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Pediatrics 131(1):189\u2013195","journal-title":"Pediatrics"},{"issue":"12","key":"1040_CR18","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121(12):1684\u20131694","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"1040_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ophtha.2010.04.021","volume":"118","author":"D Lepore","year":"2011","unstructured":"Lepore D, Molle F, Pagliara MM, Baldascino A, Angora C, Sammartino M, Quinn GE (2011) Atlas of fluorescein angiographic findings in\u00a0eyes\u00a0undergoing laser for retinopathy of prematurity. Ophthalmology 118(1):168\u2013175","journal-title":"Ophthalmology"},{"issue":"1","key":"1040_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","volume":"37","author":"B Lorenz","year":"2017","unstructured":"Lorenz B, Stieger K, J\u00e4ger M, Mais C, Stieger S, Adrassi- Dardida M (2017) Retinal vascular development with 0.312\u00a0mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study. Retina 37(1):97\u2013111","journal-title":"Retina"},{"key":"1040_CR21","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1167\/iovs.09-4403","volume":"51","author":"RS Maldonado","year":"2010","unstructured":"Maldonado RS, Izatt J, Sarin N, Wallace DK, Freedman S, Cotten CM, Toth CA (2010) Optimizing hand-held spectral domain optical coherence tomography imaging for neonates, infants, and children. Invest Ophthalmol Vis Sci 51:2678\u20132685","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1040_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jaapos.2011.12.157","volume":"16","author":"MP Blair","year":"2012","unstructured":"Blair MP, Shapiro MJ, Hartnett ME (2012) Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children. J AAPOS 16:234\u2013237","journal-title":"J AAPOS"},{"issue":"2","key":"1040_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jaapos.2013.12.009","volume":"18","author":"A Henaine-Berra","year":"2014","unstructured":"Henaine-Berra A, Garcia-Aguirre G, Quiroz-Mercado H, Martinez-Castellanos MA (2014) Retinal\u00a0fluorescein\u00a0angiographic\u00a0changes\u00a0following\u00a0intravitreal anti-VEGF therapy. J AAPOS 18(2):120\u2013123","journal-title":"J AAPOS"},{"key":"1040_CR24","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","volume":"98","author":"SG Tahija","year":"2014","unstructured":"Tahija SG, HersetyatiR Lam GC, Kusaka S, Mc Melamine PG (2014) Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone\u00a0II\u00a0retinopathy\u00a0of\u00a0prematurity. Br J Ophthalmol 98:507\u2013512","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1040_CR25","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","volume":"38","author":"JM Garcia Gonzalez","year":"2017","unstructured":"Garcia Gonzalez JM, Snyder L, Blair M, Rohr A, Shapiro M, Greenwald M (2017) Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity. Retina 38(4):764\u2013772","journal-title":"Retina"},{"issue":"16","key":"1040_CR26","first-page":"31697","volume":"161\u20136420","author":"Q Huang","year":"2017","unstructured":"Huang Q, Zhang Q, Fei P, Xu Y, Lyu J, Ji X, Peng J, Li YA, Zhao P (2017) Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors. Ophthalmology 161\u20136420(16):31697\u201331699","journal-title":"Ophthalmology"},{"key":"1040_CR27","first-page":"434","volume":"32","author":"MW Stewart","year":"2012","unstructured":"Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Buenu-Lopez E, Lopez PF (2012) Pharmacokinetic rationale for dosing every 2\u00a0weeks versus 4\u00a0weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap eye). Retina 32:434\u2013457","journal-title":"Retina"},{"key":"1040_CR28","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00417-014-2867-0","volume":"253","author":"H Yetik","year":"2015","unstructured":"Yetik H, Gunay M, Sirop S, Salihoglu Z (2015) Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy: 27\u00a0month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol 253:1677\u20131683","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1040_CR29","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/eye.2015.240","volume":"30","author":"TR Padhi","year":"2016","unstructured":"Padhi TR, Das T, Rath S, Pradhan L, Sutar S, Panda KG, Modi R, Jalalli S (2016) Serial retinal evaluation of vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I. Eye (Lond) 30:392\u2013399","journal-title":"Eye (Lond)"},{"key":"1040_CR30","first-page":"1","volume":"6","author":"IC Michaelson","year":"1982","unstructured":"Michaelson IC, Benezra D, Berson D (1982) Possible metabolic mechanism modulating blood vessel development in the inner eye and their significance for vascular pathology in the definitive eye. Metab Pediatr Syst Ophthalmol 6:1\u201310","journal-title":"Metab Pediatr Syst Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-018-1040-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-018-1040-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-018-1040-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T19:06:48Z","timestamp":1574708808000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-018-1040-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,26]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1040"],"URL":"https:\/\/doi.org\/10.1007\/s10792-018-1040-x","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,26]]},"assertion":[{"value":"5 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}